DOWNLOAD PDF

Understanding the Impact of HIV-Associated Bone Marrow Alterations on Erythropoiesis

*Emmanuel Ifeanyi Obeagu1, Getrude Uzoma Obeagu2, Esther Ugo Alum3,4 and Okechukwu Paul-Chima Ugwu4

1Department of Medical Laboratory Science, Kampala International University, Uganda.

2School of Nursing Science, Kampala International University, Uganda.

3Department of Biochemistry, Ebonyi State, Abakaliki, Ebonyi State, Nigeria

4Department of Publication and Extensions, Kampala International University, Uganda.

*Corresponding author: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda.

E-mail: emmanuelobeagu@yahoo.com, obeagu.emmanuel@kiu.ac.ug   

ORCID: 0000-0002-4538-0161          

ABSTRACT

Human Immunodeficiency Virus (HIV) infection presents a multifaceted challenge, extending beyond its primary impact on the immune system to affect various organ systems. Among these, the bone marrow, the primary site for hematopoiesis, undergoes substantial alterations during HIV infection, profoundly influencing erythropoiesis—the process of red blood cell production. Anemia, a prevalent hematologic complication in HIV-infected individuals, often serves as a marker of disease progression and impacts overall health outcomes. This paper aims to delve into the intricate relationship between HIV-associated bone marrow alterations and their consequential effects on erythropoiesis. The mechanisms underlying bone marrow changes in HIV infection, including direct viral effects, dysregulation of cytokine networks, and inflammatory processes, significantly disrupt the delicate balance necessary for efficient erythropoiesis. The impact of these alterations on erythropoiesis manifests through ineffective red blood cell production, decreased erythropoietin responsiveness, and shortened red blood cell lifespan. Chronic inflammation further complicates erythropoietic processes, contributing to the development and perpetuation of anemia in HIV-infected individuals. Therapeutic interventions encompass a multifaceted approach, including antiretroviral therapy (ART) to control viral replication, erythropoiesis-stimulating agents, and adjunctive nutritional support to manage anemia. However, emerging research targeting bone marrow microenvironmental factors and novel agents stimulating erythropoiesis offer promising avenues for future therapeutic development.

Keywords: HIV, bone marrow, erythropoiesis, erythropoietin, antiretroviral therapy

INTRODUCTION

Human Immunodeficiency Virus (HIV) infection has emerged as a global health challenge, impacting millions of lives worldwide. Beyond its well-documented effects on the immune system, HIV infection profoundly influences various organ systems, including the bone marrow, a vital hub for hematopoiesis. The intricate relationship between HIV-associated bone marrow alterations and their consequential effects on erythropoiesis, the process of red blood cell production, presents a complex yet crucial aspect of the disease’s pathophysiology [1-10]. Hematologic complications, notably anemia, are prevalent among individuals living with HIV and often serve as significant indicators of disease progression and prognosis. The bone marrow, traditionally recognized for its role in generating blood cells, undergoes a series of intricate changes during HIV infection. These alterations disrupt the finely orchestrated hematopoietic process, specifically affecting erythropoiesis, and contribute substantially to the development and perpetuation of anemia in this population [11-21].

Understanding the nuanced interplay between HIV-induced bone marrow alterations and their subsequent impact on erythropoiesis is fundamental in addressing anemia and improving the overall quality of life for individuals affected by HIV. This review endeavors to comprehensively explore the mechanisms underpinning HIV-associated bone marrow changes, elucidating their profound effects on erythropoiesis, and shedding light on therapeutic avenues and research directions aimed at managing anemia in this context [22-32]. By examining the intricate dynamics within the bone marrow microenvironment during HIV infection and unraveling their repercussions on erythropoietic processes, this review seeks to contribute to the broader understanding of hematologic complications in HIV and to pave the way for targeted interventions aimed at ameliorating anemia and enhancing the well-being of individuals affected by this complex viral disease.

HIV-Associated Bone Marrow Alterations

HIV infection is known to induce a spectrum of alterations within the bone marrow, the primary site for hematopoiesis. These changes significantly impact the bone marrow microenvironment, disrupting the intricate balance necessary for efficient hematopoietic function [33-36].  HIV exhibits a predilection for hematopoietic progenitor cells and bone marrow stromal elements. Direct infection of these cells contributes to their dysfunction, affecting their ability to support normal hematopoiesis. The virus alters the differentiation and proliferation of hematopoietic stem cells, impeding their capacity to generate mature blood cells [37-43]. HIV infection triggers dysregulated cytokine production and signaling within the bone marrow microenvironment. Elevated levels of pro-inflammatory cytokines such as TNF-α, IL-6, and IFN-γ disrupt the homeostasis necessary for proper hematopoietic function. This dysregulation contributes to impaired hematopoiesis, including erythropoiesis [44-49]. Chronic inflammation induced by HIV infection has a profound impact on the bone marrow. Persistent immune activation and inflammation adversely affect hematopoietic stem cell function and differentiation, leading to alterations in the cellular composition of the bone marrow and compromising its ability to support erythropoiesis [50-55]. Opportunistic infections, commonly associated with HIV, can directly affect the bone marrow. These infections, such as Mycobacterium avium complex and cytomegalovirus, can cause bone marrow suppression, exacerbating the already compromised hematopoietic function seen in HIV [56-61]. While ART is essential in controlling viral replication and reducing the systemic impact of HIV, some antiretroviral drugs have been associated with hematologic side effects. Certain medications may directly or indirectly affect bone marrow function, leading to alterations in hematopoiesis [62-67]. Overall, the cumulative effect of these alterations within the bone marrow during HIV infection results in a compromised hematopoietic microenvironment. These changes disrupt the normal processes of erythropoiesis and other blood cell production, contributing to the development of anemia and other hematologic complications commonly observed in individuals living with HIV. Understanding these bone marrow alterations is crucial for developing targeted therapeutic strategies to mitigate their impact on hematopoiesis and improve the overall health outcomes of HIV-infected individuals.

Impact on Erythropoiesis

The impact of HIV-associated bone marrow alterations on erythropoiesis, the process responsible for red blood cell production, is multifaceted and significantly contributes to the development of anemia in individuals living with HIV [68-70].  HIV-induced alterations in the bone marrow microenvironment led to ineffective erythropoiesis. Disruption of hematopoietic stem cell function, impaired differentiation, and decreased production of erythroid progenitor cells contribute to a diminished capacity for efficient red blood cell generation [71]. HIV infection, along with chronic inflammation and immune activation, can lead to increased destruction of red blood cells, resulting in a shortened lifespan of these cells. This accelerated turnover contributes to a state of chronic anemia [72]. Erythropoietin, a hormone crucial for regulating red blood cell production, may be affected by HIV-related alterations in the bone marrow. Some individuals with HIV-associated anemia exhibit reduced responsiveness to erythropoietin, further hindering the compensatory mechanism to increase red blood cell production [73-86]. HIV infection and its associated complications often lead to nutritional deficiencies and comorbid conditions that impact erythropoiesis. Malnutrition, gastrointestinal disturbances, and chronic infections can exacerbate anemia by reducing the availability of essential nutrients required for red blood cell production. Certain medications used in HIV management, particularly chemotherapy for associated infections or malignancies, can induce bone marrow suppression. This suppression directly affects erythropoiesis, leading to decreased red blood cell production and worsening anemia. The collective impact of these factors on erythropoiesis results in a state of chronic anemia commonly observed in individuals living with HIV. Anemia, characterized by reduced red blood cell count and hemoglobin levels, contributes to fatigue, weakness, and impaired quality of life. Understanding the intricate interplay between HIV-induced bone marrow alterations and their consequences on erythropoiesis is crucial for developing targeted interventions aimed at ameliorating anemia and improving overall health outcomes in HIV-infected individuals. Strategies focusing on managing bone marrow dysfunction, optimizing erythropoietin responses, addressing nutritional deficiencies, and minimizing medication-induced bone marrow suppression are integral components in the holistic management of anemia in the context of HIV.

Implications for Health Policy Makers

Understanding the intricate relationship between HIV-associated bone marrow alterations and their impact on erythropoiesis holds significant implications for health policy makers in devising effective strategies to address anemia and improve the overall health outcomes of individuals living with HIV. Several key considerations can guide health policy formulation and implementation:

Integrated Care Approach: Health policies should advocate for an integrated care approach that acknowledges the multifaceted nature of HIV-related complications, including anemia stemming from bone marrow alterations. Comprehensive healthcare models that address both HIV management and hematologic complications such as anemia within the same framework can enhance patient outcomes.

Access to Antiretroviral Therapy (ART): Ensuring universal access to timely and continuous ART is pivotal. Health policies should prioritize initiatives that facilitate early HIV diagnosis, promote adherence to treatment, and expand access to antiretroviral medications. Viral suppression through ART not only mitigates bone marrow alterations caused by uncontrolled viral replication but also indirectly improves erythropoiesis and reduces the burden of anemia.

Screening and Management Protocols for Anemia: Health policy guidelines should incorporate standardized screening protocols for anemia in HIV-infected individuals, enabling early identification and management of this prevalent complication. Access to diagnostic tools and interventions, such as erythropoiesis-stimulating agents and iron supplementation, should be ensured to effectively manage anemia.

Nutritional Support Programs: Policies promoting nutritional support programs tailored for individuals living with HIV can address malnutrition, a contributing factor to anemia. Ensuring access to adequate nutrition and addressing nutritional deficiencies through targeted interventions can positively impact erythropoiesis and overall health outcomes.

Research and Development Funding: Health policies should allocate resources for research initiatives focused on understanding the mechanisms underlying bone marrow alterations in HIV and their specific impacts on erythropoiesis. Funding support for studies investigating novel therapeutic interventions targeting bone marrow dysfunction and anemia in HIV-infected populations is crucial.

Training and Education for Healthcare Providers: Policies should emphasize the importance of continuous training and education for healthcare providers to enhance their awareness and competence in managing hematologic complications, including anemia, in individuals living with HIV. This includes staying updated on evolving treatment strategies and best practices.

CONCLUSION

In conclusion, the intricate relationship between HIV-associated bone marrow alterations and their profound impact on erythropoiesis presents a crucial area of consideration in managing hematologic complications, particularly anemia, in individuals living with HIV. The complexities arising from bone marrow dysfunctions during HIV infection significantly contribute to the development and perpetuation of anemia, adversely affecting the quality of life and overall health outcomes of affected individuals. Therapeutic strategies centered on viral suppression through widespread access to antiretroviral therapy (ART) constitute a cornerstone in mitigating bone marrow alterations caused by uncontrolled HIV replication. Additionally, optimizing erythropoietin responses, managing nutritional deficiencies, and implementing screening protocols for timely diagnosis and management of anemia are crucial components in holistic patient care. Health policy makers play a pivotal role in shaping initiatives that foster integrated care models, ensure universal access to ART, advocate for standardized screening protocols, support nutritional interventions, allocate resources for research endeavors, and promote ongoing education for healthcare providers. These policies serve as the foundation for a comprehensive approach aimed at managing anemia and improving overall health outcomes in HIV-infected populations.

REFERENCES

  1. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-5.
  2. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-9.
  3. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS. Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal Teaching Hospital Abakaliki Ebonyi State. Arch Blood Transfus Disord. 2018;1(2).
  4. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC. Vitamin D and insulin resistance in HIV sero positive individuals in Umudike. Int. J. Curr. Res. Med. Sci. 2018;4(2):104-8.
  5. Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK. A Review on blood borne viral infections: universal precautions. Int. J. Adv. Res. Biol. Sci. 2018;5(6):60-6.
  6. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB. Assessment of some haematological and biochemical parametrs in HIV patients before receiving treatment in Aba, Abia State, Nigeria. Res J Pharma Biol Chem Sci. 2014; 5:825-30.
  7. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebo QB, Eze GC. Pattern of total white blood cell and differential count values in HIV positive patients receiving treatment in Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria. International Journal of Life Science, Biotechnology and Pharama Research. 2014; 391:186-9.
  8. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035. 2023; 3 (1): 7-12.
  9. Oloro OH, Obeagu EI. A Systematic Review on Some Coagulation Profile in HIV Infection. International Journal of Innovative and Applied Research. 2022;10(5):1-1.
  10. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Ezemma MC, Okpomeshine EA, Ozims SJ, Agu GC. Alterations in superoxide dismutiase, vitamins C and E in HIV infected children in Umuahia, Abia state. International Journal of Advanced Research in Biological Sciences. 2015;2(11):268-71.
  11. O’Brien ME, Kupka R, Msamanga GI, Saathoff E, Hunter DJ, Fawzi WW. Anemia is an independent predictor of mortality and immunologic progression of disease among women with HIV in Tanzania. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2005 Oct 1;40(2):219-25.
  12. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sickle Cell Anaemia. NEWPORT INTERNATIONAL JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES (NIJSES). 2023;3(2):56-9.
  13. Ifeanyi OE, Obeagu GU. The Values of CD4 Count, among HIV Positive Patients in FMC Owerri. Int. J. Curr. Microbiol. App. Sci. 2015;4(4):906-10. https://www.academia.edu/download/38320134/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma.EMMA2.pdf.
  14. Obeagu EI, Okeke EI, Anonde Andrew C. Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia state, Nigeria. Int. J. Curr. Res. Biol. Med. 2016;1(2):1-5.
  15. Alum EU, Ugwu OP, Obeagu EI, Okon MB. Curtailing HIV/AIDS Spread: Impact of Religious Leaders. Newport International Journal of Research in Medical Sciences (NIJRMS). 2023;3(2):28-31.
  16. Obeagu EI, Obeagu GU, Paul-Chima UO. Stigma Associated With HIV. AIDS: A Review. Newport International Journal of Public Health and Pharmacy (Nijpp). 2023;3(2):64-7.
  17. Alum EU, Obeagu EI, Ugwu OP, Aja PM, Okon MB. HIV Infection and Cardiovascular diseases: The obnoxious Duos. Newport International Journal of Research in Medical Sciences (NIJRMS). 2023;3(2):95-9.
  18. Ibebuike JE, Nwokike GI, Nwosu DC, Obeagu EI. A Retrospective Study on Human Immune Deficiency Virus among Pregnant Women Attending Antenatal Clinic in Imo State University Teaching Hospital. International Journal of Medical Science and Dental Research, 2018; 1 (2):08-14. https://www.ijmsdr.org/published%20paper/li1i2/A%20Retrospective%20Study%20on%20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%20Attending%20Antenatal%20Clinic%20in%20Imo%20State%20University%20Teaching%20Hospital.pdf.
  19. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. Madonna University journal of Medicine and Health Sciences. 2022 ;2(3):120-7.
  20. Obeagu EI, Alum EU, Obeagu GU. Factors associated with prevalence of HIV among youths: A review of Africa perspective. Madonna University journal of Medicine and Health Sciences. 2023;3(1):13-8. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/93.
  21. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023;3(1):7-12.
  22. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. J Pub Health Nutri. 2023; 6 (2). 2023;141:1-2. links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf.
  23. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-9.
  24. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. Int J Curr Res Med Sci. 2017;3(1): 21-38.DOI:22192/ijcrms.2017.03.01.004
  25. Obeagu EI, Obeagu GU, Musiimenta E, Bot YS, Hassan AO. Factors contributing to low utilization of HIV counseling and testing services. Int. J. Curr. Res. Med. Sci. 2023;9(2): 1-5.DOI:22192/ijcrms.2023.09.02.001
  26. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;129. links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf.
  27. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-9.
  28. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-9.
  29. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. Journal of Pharmaceutical Research International. 2020;32(22):101-9.
  30. Obeagu EI, Eze VU, Alaeboh EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. J BioInnovation. 2016;5:464-71. links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf.
  31. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. International Journal of Current Microbiology and Applied Sciences. 2015;4(4):911-6. https://www.academia.edu/download/38320140/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma2.EMMA1.pdf.
  32. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. Int. J. Adv. Res. Biol. Sci. 2016;3(10): 55-65.DOI;22192/ijarbs.2016.03.10.009
  33. Pascutti MF, Erkelens MN, Nolte MA. Impact of viral infections on hematopoiesis: from beneficial to detrimental effects on bone marrow output. Frontiers in immunology. 2016; 7:364.
  34. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-5. links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf
  35. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. Madonna University journal of Medicine and Health Sciences. 2022;2(3):110-9.
  36. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. Nigeria. J. Bio. Innov. 2016;5(1):24-30. links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf.
  37. Nasiri K, Mohammadzadehsaliani S, Kheradjoo H, Shabestari AM, Eshaghizadeh P, Pakmehr A, Alsaffar MF, Al-Naqeeb BZ, Yasamineh S, Gholizadeh O. Spotlight on the impact of viral infections on Hematopoietic Stem Cells (HSCs) with a focus on COVID-19 effects. Cell Communication and Signaling. 2023;21(1):1-5.
  38. Igwe CM, Obeagu IE, Ogbuabor OA. Clinical characteristics of people living with HIV/AIDS on ART in 2014 at tertiary health institutions in Enugu, Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;130. links/645a166f5762c95ac3817d32/Clinical-characteristics-of-people-living-with-HIV-AIDS-on-ART-in-2014-at-tertiary-health-institutions-in-Enugu.pdf.
  39. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. Int J Curr Res Aca Rev. 2015; 3:139-44. https://www.academia.edu/download/38320159/Obeagu_Emmanuel_Ifeanyi3__et_al.IJCRAR.pdf.
  40. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. Ann Clin Lab Res. 2018;6(1):1-4. links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf
  41. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. Int. J. Curr. Res. Med. Sci. 2017;3(2): 28-34.DOI:22192/ijcrms.2017.03.02.005
  42. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Science Reports. 2023;6(8): e1450.
  43. Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. J Pub Health Nutri. 2023; 6 (1). 2023;139. links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf.
  44. Camacho V, McClearn V, Patel S, Welner RS. Regulation of normal and leukemic stem cells through cytokine signaling and the microenvironment. International journal of hematology. 2017; 105:566-77.
  45. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. Madonna University journal of Medicine and Health Sciences. 2022 Dec 20;2(3):128-34. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86.
  46. Walter O, Anaebo QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. Journal of Pharmaceutical Research International. 2022:29-34.
  47. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three levels of care in cross River State, Nigeria. Journal of Pharmaceutical Research International. 2020;32(24):9-18.
  48. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. J Pub Health Nutri. 2022; 5 (8). 2022;137. links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf.
  49. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. Int. J. Adv. Res. Biol. Sci. 2023;10(9):135-42.DOI:22192/ijarbs.2023.10.09.015 links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf
  50. Lewis DE, Couturier JP. Chronic Inflammation in HIV Pathogenesis: Effects on Immune Cells, Organ Systems, and Systemic Consequences. InTranslational Inflammation 2019: 111-131. Academic Press.
  51. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. Int. J. Adv. Res. Biol. Sci. 2023;10(9):128-34.DOI:22192/ijarbs.2023.10.09.014 links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf.
  52. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfected with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2017;3(5):100-4.DOI:22192/ijcrms.2017.03.05.014 https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfected_with_HIV.pdf
  53. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. South Asian Journal of Research in Microbiology. 2022;13(2):26-31.
  54. Viola N, Kimono E, Nuruh N, Obeagu EI. Factors Hindering Elimination of Mother to Child Transmission of HIV Service Uptake among HIV Positive Women at Comboni Hospital Kyamuhunga Bushenyi District. Asian Journal of Dental and Health Sciences. 2023 ;3(2):7-14. http://ajdhs.com/index.php/journal/article/view/39.
  55. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. J Clin Commun Med. 2020;2(3):180-83.DOI: DOI: 32474/JCCM.2020.02.000137 links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ElISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf.
  56. Tan IL, Smith BR, von Geldern G, Mateen FJ, McArthur JC. HIV-associated opportunistic infections of the CNS. The Lancet Neurology. 2012;11(7):605-17.
  57. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. Journal of Pharmaceutical Research International. 2021;33(47A):78-84.
  58. Emannuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. Asian Journal of Pregnancy and Childbirth. 2023;6(1):203-11. http://research.sdpublishers.net/id/eprint/2819/.
  59. Igwe MC, Obeagu EI, Ogbuabor AO, Eze GC, Ikpenwa JN, Eze-Steven PE. Socio-Demographic Variables of People Living with HIV/AIDS Initiated on ART in 2014 at Tertiary Health Institution in Enugu State. Asian Journal of Research in Infectious Diseases. 2022;10(4):1-7.
  60. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. Journal of Pharmaceutical Research International. 2021;33(57A):360-8.
  61. Igwe MC, Obeagu EI, Ogbuabor AO. Analysis of the Factors and Predictors of Adherence to Healthcare of People Living with HIV/AIDS in Tertiary Health Institutions in Enugu State. Madonna University journal of Medicine and Health Sciences. 2022;2(3):42-57. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/75.
  62. Hima Bindu A, Naga Anusha P. Adverse effects of highly active anti-retroviral therapy (HAART). J Antivir Antiretrovir. 2011;3(4):60-4.
  63. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035. 2022;2(3):6-15. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69
  64. Echendu GE, Vincent CC, Ibebuike J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. Weights Of Infants Born to HIV Infected Mothers: A Prospective Cohort Study in Federal Medical Centre, Owerri, Imo State. European Journal of Pharmaceutical and Medical Research, 2023; 10(8): 564-568
  65. Nwosu DC, Nwanjo HU, Okolie NJ, Ikeh K, Ajero CM, Dike J, Ojiegbe GC, Oze GO, Obeagu EI, Nnatunanya I, Azuonwu O. Biochemical Alterations in Adult HIV Patients on Antiretrqviral Therapy. World Journal of Pharmacy and Pharmaceutical Sciences, 2015; 4(3): 153-160. links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETRQVIRAL-THERAPY.pdf.
  66. Obeagu EI, Obeagu GU. Effect of CD4 Counts on Coagulation Parameters among HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. Int. J. Curr. Res. Biosci. Plant Biol. 2015;2(4):45-9.
  67. Obeagu EI, Nwosu DC. Adverse drug reactions in HIV/AIDS patients on highly active antiretro viral therapy: a review of prevalence. Int. J. Curr. Res. Chem. Pharm. Sci. 2019;6(12):45-8.DOI:22192/ijcrcps.2019.06.12.004 links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf.
  68. Herd CL, Mellet J, Mashingaidze T, Durandt C, Pepper MS. Consequences of HIV infection in the bone marrow niche. Frontiers in Immunology. 2023;14.
  69. Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in Human Immunodeficiency Virus infections. Int. J. Curr. Res. Med. Sci. 2023;9(2):6-13.DOI:22192/ijcrms.2023.09.02.002 links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf.
  70. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2016;2(4):29-33. links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf
  71. Wang X, Chen M, Ma S, Ding Y, Zhou C, Yuan Y. HIV-1 Tat Protein-Mediated Inflammatory Response Inhibits the Erythroid Hematopoietic Support Function of Bone Marrow Mesenchymal Stem Cells. AIDS Research and Human Retroviruses. 2022;38(9):753-63.
  72. Hunt PW. HIV and inflammation: mechanisms and consequences. Current HIV/AIDS Reports. 2012; 9:139-47.
  73. Obeagu EI, Okoroiwu IL, Obeagu G. Molecular mechanism and systemic response of erythropoietin: A Review. Int. J. Adv. Res. Biol. Sci. 2015;2(7):58-62.
  74. Obeagu EI, Obeagu GU, Nchuma BO, Amazue PO. A Review on erythropoietin receptor (EpoR). Int. J. Adv. Res. Biol. Sci. 2015;2(8):80-4.
  75. Obeagu EI. Erythropoeitin in Sickle Cell Anaemia: A Review. International Journal of Research Studies in Medical and Health Sciences. 2020;5(2):22-8.
  76. Obeagu EI, Okoroiwu II, Ezimah AC. Evaluation of serum erythropoietin levels in chronic kidney disease patients in Federal Medical centre, Umuahia, Nigeria. Int. J. Curr. Res. Biol. Med. 2016;1(4):15-21.
  77. Ifeanyi OE. A review on erythropoietin. Int J Adv Res Biol Sci. 2015;2(4):35-47.
  78. Obeagu EI, Ezimah AC, Obeagu GU. Erythropoietin in the anaemias of pregnancy: a review. Int J Curr Res Chem Pharm Sci. 2016;3(3):10-8.
  79. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2016;2(4):29-33.
  80. Ifeanyi OE, Uzoma OG. A review on erythropietin in pregnancy. J. Gynecol. Womens Health. 2018;8(3):1-4.
  81. Obeagu EI. Erythrocyte enumeration and serum erythropoietin in chronic kidney disease patients: A study in Federal Medical Centre, Umuahia, Nigeria. International Journal of Advanced Research in Biological Sciences. 2016;3(7):163-70.
  82. Nnodim J, Uche U, Ifeoma U, Chidozie N, Ifeanyi O, Oluchi AA. Hepcidin and erythropoietin level in sickle cell disease. British Journal of Medicine and Medical Research. 2015 Jan 10;8(3):261-5.
  83. Obeagu EI, Ezimah AC, Obeagu GU. Erythropoietin in hypertension: A review. J. Biol. Chem. Research. 2016;33(1):261-78.
  84. Obeagu EI, Obeagu GU, Anaebo QB. Studies on Serum Erythropoietin and Red Cell Indices of Patients with Urinary Tract Infection in Southeast, Nigeria. Saudi Journal of Biomedical Research. 2019;4(10):333-7.
  85. Obeagu EI, Abdirahman BF, Bunu UO, Obeagu GU. Obsterics characteristics that effect the newborn outcomes. Int. J. Adv. Res. Biol. Sci. 2023;10(3):134-43.
  86. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR, Ugwu OP. Hematologic Support in HIV Patients: Blood Transfusion Strategies and Immunological Considerations. APPLIED SCIENCES (NIJBAS). 2023;3(3).

CITE AS: Emmanuel Ifeanyi Obeagu, Getrude Uzoma Obeagu, Esther Ugo Alum and Okechukwu Paul-Chima Ugwu (2023). Understanding the Impact of HIV-Associated Bone Marrow Alterations on Erythropoiesis. INOSR Scientific Research 10(1):1-11. https://doi.org/10.59298/INOSRSR/2023/1.2.12222

DOWNLOAD PDF